CFHR2

Summary

CFHR2 (complement factor H related 2, HGNC:4890) is a protein-coding gene on chromosome 1q31.3, encoding Complement factor H-related protein 2 (P36980). Involved in complement regulation.

This gene belongs to a family of complement factor H-related genes (CFHR), which are clustered together with complement factor H gene on chromosome 1, and are involved in regulation of complement. Mutations in CFHR genes have been associated with dense deposit disease and atypical haemolytic-uraemic syndrome. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 3080 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_005666

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4890
Approved symbol	CFHR2
Name	complement factor H related 2
Location	1q31.3
Locus type	gene with protein product
Status	Approved
Aliases	FHR2
Ensembl gene	ENSG00000080910
Ensembl biotype	protein_coding
OMIM	600889
Entrez	3080

Gene structure

Transcript identifiers

Ensembl transcripts: 54 — 51 protein_coding, 3 retained_intron

ENST00000367415, ENST00000367421, ENST00000473386, ENST00000476712, ENST00000485647, ENST00000489703, ENST00000496448, ENST00000647617, ENST00000649283, ENST00000649960, ENST00000699921, ENST00000699922, ENST00000884517, ENST00000884518, ENST00000884519, ENST00000884520, ENST00000884521, ENST00000884522, ENST00000884523, ENST00000884524, ENST00000884525, ENST00000884526, ENST00000884527, ENST00000884528, ENST00000884529, ENST00000884530, ENST00000884531, ENST00000884532, ENST00000884533, ENST00000884534, ENST00000884535, ENST00000884536, ENST00000884537, ENST00000884538, ENST00000884539, ENST00000884540, ENST00000884541, ENST00000884542, ENST00000884543, ENST00000884544, ENST00000884545, ENST00000884546, ENST00000884547, ENST00000884548, ENST00000884549, ENST00000884550, ENST00000884551, ENST00000884552, ENST00000884553, ENST00000884554, ENST00000884555, ENST00000884556, ENST00000884557, ENST00000884558

RefSeq mRNA: 3 — MANE Select: NM_005666 NM_001312672, NM_001410924, NM_005666

CCDS: CCDS30959, CCDS91135, CCDS91136

Canonical transcript exons

ENST00000367415 — 5 exons

Exon	Start	End
ENSE00001920108	196943738	196943938
ENSE00003745979	196949455	196949649
ENSE00003831930	196950852	196951028
ENSE00003836915	196957891	196958073
ENSE00003843688	196958881	196959622

Expression profiles

Bgee: expression breadth ubiquitous, 139 present calls, max score 99.48.

Top tissues by expression

235 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.48	gold quality
liver	UBERON:0002107	98.69	gold quality
parietal pleura	UBERON:0002400	82.83	silver quality
mucosa of paranasal sinus	UBERON:0005030	82.71	silver quality
left ventricle myocardium	UBERON:0006566	81.88	gold quality
palpebral conjunctiva	UBERON:0001812	80.92	silver quality
pleura	UBERON:0000977	80.73	silver quality
upper arm skin	UBERON:0004263	80.50	silver quality
buccal mucosa cell	CL:0002336	79.06	silver quality
diaphragm	UBERON:0001103	78.49	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.98	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.50	silver quality
visceral pleura	UBERON:0002401	76.39	silver quality
germinal epithelium of ovary	UBERON:0001304	76.33	silver quality
decidua	UBERON:0002450	76.00	silver quality
choroid plexus epithelium	UBERON:0003911	74.23	silver quality
mucosa of urinary bladder	UBERON:0001259	72.78	silver quality
epithelium of nasopharynx	UBERON:0001951	72.22	silver quality
cartilage tissue	UBERON:0002418	71.69	silver quality
tibialis anterior	UBERON:0001385	70.87	silver quality
layer of synovial tissue	UBERON:0007616	70.74	silver quality
tendon of biceps brachii	UBERON:0008188	70.71	silver quality
mammary duct	UBERON:0001765	70.65	silver quality
epithelium of mammary gland	UBERON:0003244	70.10	silver quality
deltoid	UBERON:0001476	69.99	silver quality
endothelial cell	CL:0000115	69.93	silver quality
lower lobe of lung	UBERON:0008949	69.72	gold quality
seminal vesicle	UBERON:0000998	68.56	silver quality
epithelial cell of pancreas	CL:0000083	67.96	silver quality
mammalian vulva	UBERON:0000997	67.41	silver quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10553	yes	34.83
E-MTAB-6386	no	2.01
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting CFHR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-633	98.35	69.45	1167

Literature-anchored findings (GeneRIF, showing 7)

• Thus CFHR2 likely acts in concert with factor H, as CFHR2 inhibits convertases while simultaneously allowing factor H assisted degradation by factor I. (PMID:24260121)
• Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. (PMID:24333077)
• A hybrid CFHR2-CFHR5 plasma protein, arising from a chromosomal deletion mutation stabilizes the C3 convertase and reduces factor H-mediated convertase decay. (PMID:24334459)
• Studies indicate that complement factor H-related proteins (FHR1-5) may enhance complement activation, with important implications for the role of these proteins in disease. (PMID:25979655)
• Next-generation sequencing of the CFH region identified putatively functional variants (missense, splice site and indel) on the four common haplotypes. We found no expression of any of the five CFH-related genes in the retina or RPE/Choroid/Sclera, in contrast to the liver, which is the main source of the circulating proteins. [CFHR2] (PMID:27196323)
• Studies indicate an association between CFHR2-rs2986127 and acute anterior uveitis (AAU) diagnosis. (PMID:27306586)
• Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. (PMID:34260947)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cfhr1	ENSMUSG00000057037
rattus_norvegicus	Cfhr1	ENSRNOG00000042901

Paralogs (39): CFH (ENSG00000000971), SELE (ENSG00000007908), C8B (ENSG00000021852), C6 (ENSG00000039537), SEZ6 (ENSG00000063015), APOH (ENSG00000091583), SEZ6L (ENSG00000100095), SUSD6 (ENSG00000100647), SRPX (ENSG00000101955), SRPX2 (ENSG00000102359), C7 (ENSG00000112936), C9 (ENSG00000113600), PAPPA2 (ENSG00000116183), CFHR3 (ENSG00000116785), CR2 (ENSG00000117322), CD46 (ENSG00000117335), CSMD2 (ENSG00000121904), C4BPA (ENSG00000123838), C4BPB (ENSG00000123843), CFHR4 (ENSG00000134365), CFHR5 (ENSG00000134389), F13B (ENSG00000143278), SUSD4 (ENSG00000143502), C8A (ENSG00000157131), SUSD3 (ENSG00000157303), CSMD3 (ENSG00000164796), SVEP1 (ENSG00000165124), C2 (ENSG00000166278), SELP (ENSG00000174175), SEZ6L2 (ENSG00000174938), PRF1 (ENSG00000180644), PAPPA (ENSG00000182752), CSMD1 (ENSG00000183117), SELL (ENSG00000188404), CD55 (ENSG00000196352), CR1L (ENSG00000197721), CR1 (ENSG00000203710), CFB (ENSG00000243649), CFHR1 (ENSG00000244414)

Protein

Protein identifiers

Complement factor H-related protein 2 — P36980 (reviewed: P36980)

Alternative names: DDESK59, H factor-like 3, H factor-like protein 2

All UniProt accessions (9): P36980, A0A3B3IQ51, A0A3B3IRW0, A0A3B3IS00, A0A3B3IS28, A0A3B3ISW6, A0A8V8TPL2, A0A8V8TQS1, V9GYE7

UniProt curated annotations — full annotation on UniProt →

Function. Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism.

Subunit / interactions. Head-to-tail homodimer and heterodimer with CFHR1 or CFHR5.

Subcellular location. Secreted.

Tissue specificity. Expressed by the liver and secreted in plasma.

Post-translational modifications. N-glycosylated.

Isoforms (2)

UniProt ID	Names	Canonical?
P36980-1	Long	yes
P36980-2	Short, Truncated

RefSeq proteins (3): NP_001299601, NP_001397853, NP_005657* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR051503	ComplSys_Reg/VirEntry_Med	Family

Pfam: PF00084

UniProt features (29 total): strand 10, disulfide bond 8, domain 4, signal peptide 1, chain 1, splice variant 1, sequence conflict 1, helix 1, turn 1, glycosylation site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
3ZD1	X-RAY DIFFRACTION	2
5EA0	X-RAY DIFFRACTION	2
9N1Z	X-RAY DIFFRACTION	2.31
9N20	X-RAY DIFFRACTION	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P36980-F1	90.90	0.80

Antibody-complex structures (SAbDab): 1 — 5EA0

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (8): 114–140, 149–192, 178–203, 207–257, 241–267, 23–72, 55–83, 87–129

Glycosylation sites (1): 126

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-977606	Regulation of Complement cascade

MSigDB gene sets: 88 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_PROTEIN_BINDING, COUP_01, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_BINDING, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_COMPLEMENT_ACTIVATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, BLALOCK_ALZHEIMERS_DISEASE_UP, HSIAO_LIVER_SPECIFIC_GENES, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_HUMORAL_IMMUNE_RESPONSE, AACTTT_UNKNOWN, GOBP_IMMUNE_EFFECTOR_PROCESS, GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_INTERACTION_WITH_SYMBIONT

GO Biological Process (3): complement activation (GO:0006956), negative regulation of protein binding (GO:0032091), obsolete cytolysis by host of symbiont cells (GO:0051838)

GO Molecular Function (3): complement component C3b binding (GO:0001851), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Complement cascade	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	2
immune effector process	1
activation of immune response	1
humoral immune response	1
protein activation cascade	1
regulation of protein binding	1
negative regulation of binding	1
opsonin binding	1
complement binding	1
binding	1
cellular anatomical structure	1
cellular_component	1

Protein interactions and networks

STRING

384 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CFHR2	C3	P01024	847
CFHR2	MYBPH	Q13203	724
CFHR2	C4BPB	P20851	716
CFHR2	RBMS2	Q15434	685
CFHR2	CFP	P27918	639
CFHR2	DGKE	P52429	633
CFHR2	CFB	P00751	621
CFHR2	CD55	P08174	608
CFHR2	CD46	P15529	594
CFHR2	C4A	P01028	594
CFHR2	C4A	P01028	593
CFHR2	MMACHC	Q9Y4U1	579
CFHR2	CD59	P13987	577
CFHR2	RAPGEF1	Q13905	572
CFHR2	CNDP2	Q96KP4	547

IntAct

9 interactions, top by confidence:

A	B	Type	Score
CFHR1	CFHR2	psi-mi:“MI:0915”(physical association)	0.780
CFHR1	CFHR2	psi-mi:“MI:0407”(direct interaction)	0.780
CFHR2	CFHR1	psi-mi:“MI:0915”(physical association)	0.780
CFHR2	CFHR2	psi-mi:“MI:0915”(physical association)	0.610
CFHR2	CFHR2	psi-mi:“MI:0407”(direct interaction)	0.610
C3	CFHR2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (3): CFHR1 (Affinity Capture-MS), CFHR1 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: O02839, O08569, O19124, O62685, O62837, O88174, P02749, P04003, P05160, P06909, P08174, P08603, P08607, P15529, P16109, P17690, P19070, P20023, P26644, P33703, P36980, P42201, P49457, P70105, P79138, P98109, Q01339, Q02985, Q03472, Q03591, Q07968, Q22328, Q28065, Q28768, Q2VPA4, Q5R4D0, Q60401, Q60736, Q61475, Q61476

Diamond homologs: A0A182C2Z2, A0JNA2, B3EX01, E7FEC4, O08569, O19124, O57254, O62685, O62837, O88174, P08174, P0DTN2, P15529, P21115, P24083, P24084, P36980, P49457, P79138, P81475, Q01227, Q07968, Q28085, Q29RN8, Q4V9Z5, Q53EL9, Q5R4D0, Q5R8M2, Q5VX71, Q60736, Q63515, Q6AX42, Q6P1D5, Q6UXD5, Q7TSK2, Q7Z408, Q8BH32, Q9BYH1, Q9JF44, Q9W332

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	13
Benign	14

Top pathogenic / likely-pathogenic (0)

SpliceAI

808 predictions. Top by Δscore:

Variant	Effect	Δscore
1:196950873:T:TA	acceptor_gain	1.0000
1:196951029:G:GG	donor_gain	1.0000
1:196957889:A:AG	acceptor_gain	1.0000
1:196957890:G:GA	acceptor_gain	1.0000
1:196957890:G:GC	acceptor_gain	1.0000
1:196958071:TAGGT:T	donor_loss	1.0000
1:196949454:GCAAT:G	acceptor_gain	0.9900
1:196950874:G:A	acceptor_gain	0.9900
1:196957890:GT:G	acceptor_gain	0.9900
1:196957890:GTT:G	acceptor_gain	0.9900
1:196957890:GTTT:G	acceptor_gain	0.9900
1:196958069:CTTAG:C	donor_gain	0.9900
1:196958070:TTAG:T	donor_gain	0.9900
1:196958072:AG:A	donor_gain	0.9900
1:196958072:AGGT:A	donor_loss	0.9900
1:196958073:GG:G	donor_gain	0.9900
1:196958074:G:GG	donor_gain	0.9900
1:196958075:TAA:T	donor_loss	0.9900
1:196958075:TAAG:T	donor_loss	0.9900
1:196943935:GAAG:G	donor_gain	0.9800
1:196943936:AAGG:A	donor_loss	0.9800
1:196943938:GGTA:G	donor_loss	0.9800
1:196943939:G:T	donor_loss	0.9800
1:196943940:TAAG:T	donor_loss	0.9800
1:196946760:G:GT	donor_gain	0.9800
1:196951022:TCCAC:T	donor_gain	0.9800
1:196951023:CCACT:C	donor_gain	0.9800
1:196951026:CTA:C	donor_gain	0.9800
1:196958071:TAG:T	donor_gain	0.9800
1:196946761:A:T	donor_gain	0.9700

AlphaMissense

1750 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:196958051:G:C	W197C	0.996
1:196958051:G:T	W197C	0.996
1:196951000:G:C	W134C	0.994
1:196951000:G:T	W134C	0.994
1:196949627:G:C	W77C	0.990
1:196949627:G:T	W77C	0.990
1:196958049:T:A	W197R	0.989
1:196958049:T:C	W197R	0.989
1:196950998:T:A	W134R	0.985
1:196950998:T:C	W134R	0.985
1:196958067:T:A	C203S	0.984
1:196958068:G:C	C203S	0.984
1:196957986:T:G	Y176D	0.983
1:196957992:T:A	C178S	0.982
1:196957993:G:C	C178S	0.982
1:196949643:T:A	C83S	0.980
1:196949644:G:C	C83S	0.980
1:196949625:T:A	W77R	0.977
1:196949625:T:C	W77R	0.977
1:196950983:T:A	C129S	0.975
1:196950984:G:C	C129S	0.975
1:196950938:T:A	C114S	0.974
1:196950939:G:C	C114S	0.974
1:196951016:T:A	C140S	0.974
1:196951017:G:C	C140S	0.974
1:196958034:T:A	C192S	0.974
1:196958035:G:C	C192S	0.974
1:196958067:T:C	C203R	0.974
1:196959036:T:A	C257S	0.974
1:196959037:G:C	C257S	0.974

dbSNP variants (sampled 300 via entrez): RS1000669367 (1:196947449 A>G), RS1000693047 (1:196952684 C>CA), RS1000728595 (1:196951693 C>A,T), RS1000738789 (1:196946508 T>G), RS1000760253 (1:196951924 C>G), RS1000949707 (1:196957708 G>A,C), RS1001384976 (1:196956792 G>T), RS1001605980 (1:196951444 A>T), RS1001751219 (1:196957004 C>T), RS1001809321 (1:196946904 TTG>T), RS1001935820 (1:196952733 A>T), RS1001980397 (1:196951617 T>C), RS1002069082 (1:196948068 ATTGT>A), RS1002135462 (1:196947078 A>G), RS1002418424 (1:196956906 T>A)

Disease associations

OMIM: gene MIM:600889 | disease phenotypes: MIM:614809

GenCC curated gene-disease

Mondo (4): atypical hemolytic-uremic syndrome (MONDO:0016244), C3 glomerulonephritis (MONDO:0013892), kidney disorder (MONDO:0005240), complement 3 glomerulopathy (MONDO:0018013)

Orphanet (3): Atypical hemolytic uremic syndrome (Orphanet:2134), C3 glomerulonephritis (Orphanet:329931), C3 glomerulopathy (Orphanet:329918)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001899_1	Age-related macular degeneration	1.000000e-16
GCST004250_7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	9.000000e-06
GCST005212_15	Asthma	9.000000e-06
GCST006943_63	Feeling miserable	4.000000e-08
GCST90019043_1	Complement factor H-related protein 2 levels	2.000000e-29
GCST90019043_2	Complement factor H-related protein 2 levels	5.000000e-19
GCST90019043_3	Complement factor H-related protein 2 levels	2.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007965	response to combination chemotherapy
EFO:0009598	feeling miserable measurement
EFO:0600055	complement factor H-related protein 2 measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065766	Atypical Hemolytic Uremic Syndrome	C12.050.351.968.419.936.463.500; C12.200.777.419.936.463.500; C12.950.419.936.463.500; C15.378.050.141.610.500; C15.378.140.855.925.500.500; C15.378.243.937.925.500.500
D007674	Kidney Diseases	C12.050.351.968.419; C12.200.777.419; C12.950.419

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
Benzo(a)pyrene	affects methylation, decreases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
methyleugenol	decreases expression	1
sodium arsenite	decreases expression	1
chromium hexavalent ion	increases expression	1
CGP 52608	increases reaction, affects binding	1
perfluoro-n-nonanoic acid	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Copper	affects cotreatment, decreases expression	1
Endosulfan	decreases expression, affects cotreatment	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases expression	1
Zinc	decreases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02574403	PHASE4	COMPLETED	Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
NCT07308574	PHASE4	RECRUITING	Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
NCT00067990	PHASE4	COMPLETED	Angiotensin II Blockade for Chronic Allograft Nephropathy
NCT00117078	PHASE4	COMPLETED	Aranesp® Monthly Preference Study - 2
NCT00117130	PHASE4	COMPLETED	Study to Evaluate Effectiveness of Aranesp®
NCT00132431	PHASE4	COMPLETED	START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
NCT00140985	PHASE4	COMPLETED	Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
NCT00246129	PHASE4	COMPLETED	CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
NCT00275535	PHASE4	COMPLETED	The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
NCT00282217	PHASE4	COMPLETED	Study Evaluating Sirolimus in the Treatment of Kidney Transplant
NCT00289614	PHASE4	COMPLETED	Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
NCT00290069	PHASE4	UNKNOWN	Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
NCT00338468	PHASE4	TERMINATED	A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
NCT00368901	PHASE4	COMPLETED	STAAR-2 Clinical Study
NCT00369733	PHASE4	COMPLETED	STAAR-3 Clinical Study
NCT00369772	PHASE4	COMPLETED	STAAR-1 Clinical Study
NCT00379899	PHASE4	COMPLETED	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT00443508	PHASE4	UNKNOWN	Reduction or Discontinuation of CNI’s With Conversion to Everolimus-Based Immunosuppresion
NCT00452478	PHASE4	TERMINATED	Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
NCT00492518	PHASE4	COMPLETED	Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy
NCT00505102	PHASE4	UNKNOWN	Safe Renal Function In Long Term Heart Transplanted Patients
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00688480	PHASE4	COMPLETED	Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
NCT00863707	PHASE4	COMPLETED	A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT01101698	PHASE4	UNKNOWN	Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients
NCT01150201	PHASE4	COMPLETED	Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease
NCT01155141	PHASE4	COMPLETED	Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
NCT01228279	PHASE4	COMPLETED	Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
NCT01334333	PHASE4	COMPLETED	Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
NCT01437943	PHASE4	TERMINATED	Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
NCT01545479	PHASE4	COMPLETED	Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition
NCT01614431	PHASE4	COMPLETED	N Acetyl Cysteine for Cystinosis Patients
NCT01631149	PHASE4	COMPLETED	Effect of Deep BLock on Intraoperative Surgical Conditions
NCT01722513	PHASE4	UNKNOWN	Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
NCT01985360	PHASE4	COMPLETED	ISCHEMIA-Chronic Kidney Disease Trial
NCT02311010	PHASE4	UNKNOWN	Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
NCT02413073	PHASE4	COMPLETED	Whole Body Vibration in Kidney Disease
NCT02444013	PHASE4	UNKNOWN	Folic Acid for Prevention of Contrast Induced Nephropathy
NCT02663713	PHASE4	COMPLETED	A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
NCT02707809	PHASE4	COMPLETED	Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient